Testing and Targeting KRAS-Mutant NSCLC

 

ESMO 2022 Conference Coverage
J

ESMO 2022 on the Additional Practice-Informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study: Adagrasib in KRASG12Cm NSCLC

By ESMO 2022 Conference Coverage FEATURING Jun Zhang
By ESMO 2022 Conference Coverage FEATURING Jun Zhang
264 views
September 27, 2022
This video was recorded prior to the FDA granting approval to Adagrasib (Krazati) on December ...
read more ↘
0 Comments
Login to view comments. Click here to Login
Testing and Targeting KRAS-Mutant NSCLC
06:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "3-Year Results of the IFCT-1701 DICIPLE P…

Feat. A. Toffart
33:14
Benjamin Herzberg

Direct KRAS Inhibition in NSCLC: Past, Present, and Future

09:17
Shirish Gadgeel

The Data on Novel KRAS G12C Inhibitors: Focus on Adagrasib

21:21
Johns Hopkins

KRASG12C Mutation in NSCLC: Current Data and Future Directions

Feat. S. Rosner
14:37
OncoAlert

mNSCLC: Targeted Therapies Update

Feat. S. Popat
10:29
NYU Langone

FDA Approval of Adagrasib in KRAS G12Cm NSCLC

Feat. J. Sabari
08:22
ESMO 2022 Conference Coverage

ESMO 2022 on the Additional Practice-Informing Adverse Event Pattern…

Feat. J. Zhang
24:33
Paul Hofman

Assessment of Co-Occurring Genomic Alterations in NSCLC

35:51
Yale Cancer Center

Advancements in NSCLC: Multidisciplinary Case Panel Discussion

Feat. S. Benaderet, M. Cohenuram, S. Goldberg, V. Mase Jr, D. Rudolph
20:37
Jia Luo

Taking on Goliath: Targeting KRAS in NSCLC

18:14
Janakiraman Subramanian

Understanding KRAS G12C Positive Lung Cancer

29:00
GRACE

Therapeutic Options in Driver-Mutation Positive mNSCLC Refractory to…

Feat. A. Desai